

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL	
OMB Number:	3235-0104
Estimated average burden hours per	
response	0.5

See Footnote (2)

See Footnote (2)

See Footnote (2)

 $D^{(1)}$

Ι

Ι

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)									
Name and Address of Reporting Person ARMISTICE CAPITAL, LLC		Date of Event Requiring Statement (Month/Day/Year) 04/13/2018		3. Issuer Name and Ticker or Trading Symbol EYEGATE PHARMACEUTICALS INC [EYEG]					
510 MADISON AVENUE	(First) E, 22ND FLOOR	(Middle)	04/13/2018		Relationship of Reporting Person(s) to Issuer (Check all applicable) Director			5. If Amendment, Date Original Filed(Month/Day/Year)	
NEW YORK, NY 10022	(Street)				Officer (give title below)	Other (specify below		i. Individual or Joint/Group Filing(Check Applicable Line) Form filed by One Reporting Person X_Form filed by More than One Reporting Person	
(City)	(State)	(Zip)	Table I - Non-Derivative Securities Beneficially Owned						
			(Instr. 4)			4. Nature of Indirect Beneficial Ownership (Instr. 5)			
Common Stock, \$0.01 par value			3,232,530		D (1)				
Common Stock, \$0.01 par value			3,232,530		I	See Footnote (2)			
Common Stock, \$0.01 par value			3,232,530		I	See Footnote (2)			
Reminder: Report on a separate				d ! 4b! f		Ab - 6 dil		SEC 1473	(7-02)
	Persons wno	respona to the collect	ion of information conta	inea in this form are not	required to respond unle	ess the form displays a c	urrently valid	OMB control number.	

1. Title of Derivative Security (Instr. 4)			Derivative Security		Security	Derivative Security: Direct (D) or Indirect (I)	Nature of Indirect Beneficial Ownership (Instr. 5)
		Expiration Date	Title	Amount or Number of Shares		(Instr. 5)	
Warrants	06/14/2017(3)	06/14/2022	Common Stock	2,000,000	\$ 1.5	D (1)	
Warrants	06/14/2017 ⁽³⁾	06/14/2022	Common Stock	2,000,000	\$ 1.5	I	See Footnote (2)
Warrants	06/14/2017(3)	06/14/2022	Common Stock	2,000,000	\$ 1.5	I	See Footnote (2)
Warrants	04/17/2018(3)	04/17/2023	Common Stock	15,937,500	\$ 0.32	DΨ	
Warrants	04/17/2018(4)	04/17/2023	Common Stock	15.937.500	\$ 0.32	Ī	See Footnote (2)

15,937,500

12,787,500

12,787,500

\$ 0.32

\$ 0.32

\$ 0.32

\$ 0.32

04/17/2018⁽⁴⁾ 04/17/2023 Common Stock

Common Stock

Common Stock

Common Stock 12,787,500

<u>(5)</u>

(5)

(5)

04/17/2018(5)

04/17/2018⁽⁵⁾

04/17/2018⁽⁵⁾

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

Reporting Owners

Series C Convertible Preferred Stock

Series C Convertible Preferred Stock

Series C Convertible Preferred Stock

Warrants

	Relationships					
Reporting Owner Name / Address	Director	10% Owner	Officer	Other		
ARMISTICE CAPITAL, LLC 510 MADISON AVENUE, 22ND FLOOR NEW YORK, NY 10022		X				
Armistice Capital Master Fund Ltd. 510 MADISON AVENUE, 22ND FLOOR NEW YORK, NY 10022		X				
Boyd Steven 510 MADISON AVENUE, 22ND FLOOR NEW YORK, NY 10022		Х				

Signatures

Armistice Capital, LLC, By: /s/ Steven Boyd, Managing Member "Signature of Reporting Person	04/17/2018 Date
Armistice Capital Master Fund, Ltd., By:/s/ Steven Boyd, Director	04/17/2018 Date
/s/ Steven Boyd [™] Signature of Reporting Person	04/17/2018 Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 5(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The reported securities are directly owned by Armistice Capital Master Fund, Ltd.
- (2) The reported securities are directly owned by Armistice Capital Master Fund, Ltd., a Cayman Islands corporation, and may be deemed to be indirectly beneficially owned by Armistice Capital, LLC, as the investment manager of Armistice Capital Master Fund, Ltd. The reported securities
- (3) These warrants are currently excercisable, subject to a blocker provision that prevents Armistice Capital Master Fund, Ltd.from exercising the warrants if it would be more than a 4.99% beneficial owner of the Common Shares following such exercise.
- (4) These warrants are currently excercisable, subject to a blocker provision that prevents Armistice Capital Master Fund, Ltd.from exercising the warrants if it would be more than a 9.99% beneficial owner of the Common Shares following such exercise.
- (5) The Series C Convertible Preferred Stock has no expiration date and is convertible at any time at the option of Armistice Capital Master Fund, Ltd., subject to a blocker provision that prevents Armistice Capital Master Fund, Ltd.from converting the Series C Convertible Preferred Stock is

Remarks:

Armistice Capital, LLC and Steven Boyd disclaim beneficial ownership of the reported securities except to the extent of their respective pecuniary interest therein, and this report shall not be deemed an admission that either of them are the

 $Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, {\it See}\ Instruction\ 6 for procedure.$

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.